ReviewOncoTargets and therapy2018

Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy.

Rutika Mehta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.